Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27781078 | 0.98 | HSD17B10 (0.48) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL12286918 | 0.87 | HSD17B10 (0.52) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL5671061 | 0.83 | HSD17B10 (0.54) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL10724396 | 0.82 | HSD17B10 (0.47) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL13597747 | 0.81 | HSD17B10 (0.47) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL11444322 | 0.80 | GPR35 (0.47) | HSD17B10TDP1PLAUALDH1A1TSHR | |
| SCHEMBL9759856 | 0.80 | HSD17B10 (0.45) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL13982720 | 0.80 | ALDH1A1 (0.46) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL11229561 | 0.79 | HSD17B10 (0.46) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 | |
| SCHEMBL2910616 | 0.79 | HSD17B10 (0.46) | HSD17B10TDP1PLAUALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3688124-B1 | ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-10-25 | — | — | EP | claimed |
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | XIAMEN UNIVERSITY (CN) | 2018-03-08 | — | — | US | disclosed |
| US-9663454-B2 | 3-aryl propiolonitrile compounds for thiol labeling | UNIVERSITE DE STRASBOURG (FR) | 2017-05-30 | — | — | US | disclosed |
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | NANOPHARMACEUTICALS, LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | NANOPHARMACEUTICALS, LLC | 2015-01-29 | — | — | US | disclosed |
| US-8859539-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859539-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | HSD17B10 2753/4885TDP1 3490/4885PLAU 252/4885 |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | HSD17B10 2753/4885TDP1 3490/4885PLAU 252/4885 |
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SQLE, COASY, MCCC2 | HSD17B10 509/4885TDP1 4493/4885PLAU 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.